HIV Drug to Aid Melanoma Therapies? Hyungsoo Kim, Ze’ev A. Ronai  Cancer Cell  Volume 29, Issue 3, Pages 245-246 (March 2016) DOI: 10.1016/j.ccell.2016.02.014 Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 1 Nelfinavir Combination with MAPK Inhibitors in Melanoma Therapy Melanoma requires the foundation of upregulated MAPK signaling (left) and is responsive to MAPK-targeted therapies (BRAF/MEK inhibitors), which attenuate MAPK signaling, thus reducing tumor burden—albeit for a limited time before resistant tumors emerge (upper). Here, Smith et al. suggest that targeting the PAX3/MITF pathway, using the HIV protease inhibitor nelfinavir, will augment MAPK inhibitors and sensitize melanoma to therapy, and, possibly, overcome resistant phenotype. Timeline axis (bottom) remains to be populated by additional data, monitoring long-term effects of the proposed combination on resistance and metastasis. Cancer Cell 2016 29, 245-246DOI: (10.1016/j.ccell.2016.02.014) Copyright © 2016 Elsevier Inc. Terms and Conditions